Update on Class Action for MacroGenics Investors
Levi & Korsinsky, LLP is reaching out to investors in MacroGenics, Inc. (NASDAQ: MGNX) about an important class action securities lawsuit. This legal action aims to bring justice and recovery for investors who have suffered financial losses due to actions and statements made by MacroGenics during a specific time frame characterized by alleged securities fraud.
Breaking Down the Class Definition
This class action lawsuit represents a group of investors who were adversely affected by securities fraud during a defined period. In simple terms, if you bought stock in MacroGenics between early March and early May, you might be impacted by this lawsuit. The case focuses on misleading statements regarding the safety data from the company’s TAMARACK Phase 2 study.
The Allegations
During this class period, MacroGenics made significant misrepresentations about its product, vobramitamab duocarmazine, which later raised serious concerns about its safety. On the day the report was made public, investors discovered these statements did not accurately reflect the product's safety profile. The market reacted strongly, and the stock of MGNX fell sharply by 77.4%, resulting in a dramatic loss of $11.36 per share.
Important Deadlines and No Cost to You
If you’ve incurred a loss due to these events, it’s essential to act swiftly. You have until September 24, 2024, to request to be designated as a lead plaintiff by the Court. It's crucial to understand that even if you don’t end up being the lead plaintiff, you can still benefit from any potential recovery without being responsible for any costs or obligations.
Advantages of Joining
One of the most compelling reasons to consider joining this class action is that, as a member, you could receive potential compensation with no direct fees involved. This opportunity provides a means for recouping some of your losses without any upfront financial burden. If you believe your rights as an investor have been violated, this class action might be a significant way to seek redress.
Why Choose Levi & Korsinsky?
Levi & Korsinsky is a law firm with a strong track record in securities litigation, boasting decades of experience. Their team has recovered hundreds of millions for shareholders, demonstrating their expertise in managing complex legal challenges. For seven years running, the firm has consistently ranked among the Top 50 securities litigation firms in the nation, giving investors confidence that they have skilled lawyers advocating for their rights.
Expertise and Support
The strength of Levi & Korsinsky comes not only from their winning history but also from their dedicated team of over 70 professionals who are devoted to delivering excellent service to clients. They understand the intricacies of securities law and are fully equipped to handle the demands of class action litigation.
Contact Levi & Korsinsky
If you’d like more information or wish to express interest in joining the class action regarding MacroGenics, don’t hesitate to reach out to Joseph E. Levi, Esq., or Ed Korsinsky, Esq. Interested investors are encouraged to call them at (212) 363-7500 for any inquiries.
Frequently Asked Questions
What is the class action against MacroGenics meant to achieve?
The class action aims to recover losses for investors affected by alleged securities fraud that involved misrepresentations about the safety of vobramitamab duocarmazine.
How can I get involved in the class action?
Eligible investors should contact Levi & Korsinsky by the specified deadline to show their interest and possibly serve as lead plaintiffs.
What specific claims are included in the lawsuit?
The lawsuit accuses MacroGenics of misrepresenting the safety of its product, resulting in significant financial losses for investors.
Are there any costs to participate in the class action?
No, there are no costs or obligations to join as a class member; you can participate without any upfront payments for potential recovery.
Why should I consider Levi & Korsinsky for legal representation?
Levi & Korsinsky has a proven history of achieving favorable results in securities litigation and offers extensive experience and dedicated service to their clients.
